Sympathetic Nervous System Analysis for Coronary Artery Dissection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores differences in the body's "fight or flight" system (Sympathetic Nervous System) and artery health between individuals who have experienced spontaneous coronary artery dissection (SCAD) and those who have not. Participants in the SCAD group will undergo assessments of heart and blood vessel functions, while a control group of healthy individuals will do the same for comparison. Those with SCAD confirmed by specific heart scans are suitable for the SCAD group, while individuals without any heart disease are ideal candidates for the control group. As an unphased trial, this study provides participants the chance to contribute to important research that may enhance understanding and treatment of SCAD.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are actively being treated with anticoagulation (blood thinners) or dual antiplatelet therapy (medications that prevent blood clots).
What prior data suggests that this analysis is safe for participants?
Research has shown that Sympathetic Nervous System Analysis is generally safe. This process mainly involves tests to assess the body's "fight or flight" system. No reports of harmful effects from these tests exist. Since the trial observes natural body functions rather than testing a new drug or device, the risk remains low. For those concerned about safety, similar studies have not shown negative outcomes, making this approach well-tolerated for participants.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to explore the role of the sympathetic nervous system in coronary artery dissection, a condition with limited understanding and treatment options. Unlike traditional treatments that focus on managing symptoms and preventing complications, this trial seeks to uncover new insights into neurovascular function, which could lead to innovative approaches for early detection or prevention. By comparing the neurovascular function of individuals with a history of spontaneous coronary artery dissection (SCAD) to healthy controls, the trial may reveal key differences that could inform future therapeutic strategies.
What evidence suggests that this analysis is effective for assessing sympathetic function in coronary artery dissection?
Research has shown that the body's "fight or flight" system, known as the sympathetic nervous system, might link to spontaneous coronary artery dissection (SCAD). SCAD involves a tear in the heart's artery wall. This trial will compare the sympathetic nervous system and artery health between participants in the SCAD group and those in the Healthy Control Group. The aim is to understand how the nervous system might impact artery health. This research could lead to better prevention or treatment methods for SCAD. However, more data is needed to confirm the effectiveness of these approaches.12345
Who Is on the Research Team?
Marysia Tweet, MD, MS
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This study is for individuals with a history of spontaneous coronary artery dissection (SCAD), confirmed by specific heart imaging tests, and healthy volunteers without any cardiac disease. Pregnant women, those with unstable heart conditions recently, or on certain blood thinners can't participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Assessment
Participants undergo a series of diagnostic studies to assess neurovascular function
Follow-up
Participants are monitored for safety and effectiveness after diagnostic assessments
What Are the Treatments Tested in This Trial?
Interventions
- Sympathetic Nervous System Analysis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator